Tüdőrák: vizsgálatok itt: Brazília

In Brazília 68 Also abroad 2733

68 trials · From ClinicalTrials.gov, checked 2026. november 12.. Ask the study team whether a trial fits you.

2. fázisTaking people
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Where
Barretos, São Paulo
Életkor
18 év and over
People
130 worldwide
Run by
Johnson & Johnson Enterprise Innovation Inc.
See details and how to joinNCT06667908 · EU 2024-518276-32-00
2/3. fázisTaking people
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
Where
Cachoeiro de Itapemirim, Rio de Janeiro, Salvador
Életkor
18 év and over
People
750 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT07365319 · EU 2025-525013-23-00
2/3. fázisTaking people
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
Where
Barretos, Curitiba, Fortaleza, Ijuí, Itajaí, Lajeado, Londrina, Natal, Passo Fundo, Porto Alegre, Rio de Janeiro, Salvador, São Caetano do Sul, São José do Vale do Rio Preto, São Paulo, Vitória
Életkor
18 év and over
People
1580 worldwide
Run by
BioNTech SE
See details and how to joinNCT06712316 · EU 2024-515764-31-00
3. fázisTaking people
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Where
Barretos, Maceió, Natal, Porto Alegre, Santo André, São Paulo
Életkor
18 év and over
People
400 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07195695 · EU 2025-521284-12-00
2/3. fázisTaking people
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Where
Barretos, Florianópolis, Ijuí, Lajeado, Natal, Porto Alegre, Rio de Janeiro, Salvador, São José do Rio Preto, São Paulo
Életkor
18 év and over
People
626 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT04613596 · EU 2023-508922-83-00
3. fázisTaking people
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Where
Barretos, Porto Alegre, Rio de Janeiro, Salvador, São Paulo
Életkor
18 év and over
People
768 worldwide
Run by
AbbVie
See details and how to joinNCT04928846 · EU 2023-505749-14-00
3. fázisTaking people
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Where
Porto Alegre, Recife, Santa Cruz do Sul, São José do Rio Preto, São Paulo, Teresina
Életkor
18 év and over
People
851 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06422143 · EU 2023-510128-66-00
3. fázisTaking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Where
Barretos, Florianópolis, Ijuí, Londrina, Porto Alegre, Salvador, São Paulo, Taubaté
Életkor
18 év and over
People
1160 worldwide
Run by
AstraZeneca
See details and how to joinNCT06692738 · EU 2024-514281-39-00
3. fázisTaking people
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Where
Barretos, Curitiba, Florianópolis, Ipatinga, Natal, Porto Alegre, Rio de Janeiro, Santa Maria, São Paulo, Taubaté
Életkor
18 év and over
People
675 worldwide
Run by
AstraZeneca
See details and how to joinNCT06357533 · EU 2023-505077-32-00
3. fázisTaking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
Where
Ijuí, Londrina, Passo Fundo, Porto Alegre, Salvador, São Paulo, Taubaté, Vitória
Életkor
18 év and over
People
1160 worldwide
Run by
AstraZeneca
See details and how to joinNCT06627647 · EU 2024-515008-38-00
1/2. fázisTaking people
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Where
Barretos, Fortaleza, Natal, Pelotas, Porto Alegre, São Paulo
Életkor
18 év and over
People
152 worldwide
Run by
AstraZeneca
See details and how to joinNCT06996782 · EU 2024-519786-22-01
3. fázisTaking people
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Where
Barretos, Belo Horizonte, Blumenau, Ijuí, Itajaí, Porto Alegre, Porto Velho, Rio de Janeiro, Salvador, Santa Cruz do Sul, São Carlos, São José do Rio Preto, São Paulo, Vitória
Életkor
18 év and over
People
630 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT06875310 · EU 2024-515698-85-00
3. fázisTaking people
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Where
Barretos, Blumenau, Curitiba, Fortaleza, Natal, Porto Alegre, Ribeirão Preto, Rio de Janeiro, Salvador, Santo André, Sao Jose Rio Preto, São Paulo, Vila Olímpia
Életkor
18 év and over
People
686 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06899126 · EU 2024-515658-26-00
2/3. fázisTaking people
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Where
Barretos, Bauru, Blumenau, Campinas, Fortaleza, Natal, Porto Alegre, Rio de Janeiro, Santa Cruz do Sul, São Caetano do Sul, São José do Rio Preto, São Paulo, Vitória
Életkor
18 év and over
People
590 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07063745 · EU 2025-521511-40-00
3. fázisTaking people
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Where
Barretos, Fortaleza, Natal, Porto Alegre, São Paulo, Taubaté
Életkor
18 év and over
People
750 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361510 · EU 2025-523586-18-00
No phaseNot yet taking people in Brazília
Observational Study That Will Analyse the Spread and Stratification of Lung Cancer Risk Using Artificial Intelligence
Where
São Paulo
Életkor
50 év to 80 év
People
1500
Run by
AstraZeneca
See details and how to joinNCT07617636
2. fázisTaking people
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Where
Barretos, Natal/RN, Porto Alegre, São Paulo
Életkor
18 év and over
People
160 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07680764 · EU 2026-525170-19-00
2. fázisTaking people
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Where
Belém, Curitiba, Florianópolis, Fortaleza, Ijuí, Natal, Recife, São Paulo
Életkor
18 év and over
People
150 worldwide
Run by
AbbVie
See details and how to joinNCT06568939
1/2. fázisTaking people
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Natal, São José do Rio Preto, São Paulo
Életkor
18 év and over
People
430 worldwide
Run by
Bayer
See details and how to joinNCT05099172 · EU 2023-503795-24-00
3. fázisTaking people
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Where
Fortaleza Ceara, Ijuí, Natal, Porto Alegre, Recife Pernambuco, Santa Lúcia, Santo André, São Paulo
Életkor
18 év and over
People
695 worldwide
Run by
Gilead Sciences
See details and how to joinNCT06801834
3. fázisTaking people
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Where
Barretos, Belo Horizonte, Botafogo, Brasília, Cachoeiro de Itapemirim, Centro Santa Maria, Curitiba, Florianópolis, Fortaleza, Jaú, Joinville, Lajeado, Natal, Passo Fundo, Porto Alegre, Recife, Salvador, São Paulo, Sorocaba, Teresina, Vitória
Életkor
18 év and over
People
360 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT07128199 · EU 2025-521775-31-00
2. fázisTaking people
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
Where
Porto Alegre, São Paulo
Életkor
18 év and over
People
40 worldwide
Run by
Pfizer
See details and how to joinNCT07476287 · EU 2025-524686-24-00
3. fázisTaking people
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Where
Barretos, Curitiba, Florianópolis, Fortaleza, Natal, Passo Fundo, Porto Alegre, Recife, Ribeirão Preto, Rio de Janeiro, Salvador, Santo André, Sao Jose Rio Preto, São Paulo, Vitória
Életkor
18 év and over
People
1410 worldwide
Run by
Pfizer
See details and how to joinNCT07222566 · EU 2025-523461-17-01
1. fázisTaking people
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Where
Natal, Porto Alegre, São Paulo, Sorocaba
Életkor
18 év and over
People
392 worldwide
Run by
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
See details and how to joinNCT06625775 · EU 2024-519445-29-00
1/2. fázisTaking people
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
Where
Barretos, Porto Alegre, São José do Rio Preto, São Paulo
Életkor
18 év and over
People
140 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07286149 · EU 2024-512248-47-00